AI Terminal
Elanix Biotechnologies AG
Board/Management Information • Feb 7, 2019
136_rns_2019-02-07_8c919290-e5a8-45b0-86b1-df496c9142f5.html
Board/Management Information
Open in ViewerOpens in native device viewer
News Details
Ad-hoc | 7 February 2019 14:03
Elanix Biotechnologies AG: Major Shareholder requests extraordinary general assembly to replace the Chairman of the Supervisory Board
Elanix Biotechnologies AG / Key word(s): Personnel/AGM/EGM
Elanix Biotechnologies AG: Major Shareholder requests extraordinary general assembly to replace the Chairman of the Supervisory Board
07-Feb-2019 / 14:03 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Elanix Biotechnologies AG: Major Shareholder requests extraordinary general assembly to replace the Chairman of the Supervisory Board
Berlin, February 7, 2019 – The new major shareholder of Elanix Biotechnologies AG (“Company”, “Elanix”), Mrs. Fang Bao, has announced that she requests to convene an extraordinary shareholder meeting to replace the chairman of the supervisory board, Mr. Jürgen Kullmann.
His deputy, Mrs. Abigael de Buys Roessingh, announced today to resign from the Supervisory Board with effect from 8 March 2019. A successor should be appointed by juridical order in a timely manner.
Mrs. Fang Bao will remain in office as Supervisory Board member. A date and the agenda for the General Meeting have not yet been announced. The Management Board will keep the shareholders informed.
Lee-Ann Laurent-Applegate
CEO
Contacts
Elanix Biotechnologies AG
Lee-Ann Laurent-Applegate
Tel: +41 (0)22 363 66 40
About Elanix
Elanix develops and commercializes tissue regeneration products for acute wound care, dermatological and gynecological applications, and provides services in cell technologies. The company was founded in 2012 as a spin-out from the University Hospital of Lausanne (CHUV), Switzerland, to commercialize a patented human progenitor cell technology. Progenitor cells are fully differentiated yet immunologically neutral cells that are very potent inducers of tissue growth and healing. Elanix owns GMP certified Master and Working human cell banks with vast quantities of cells.
Forward-looking statements
This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.
07-Feb-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
| Language: | English |
| Company: | Elanix Biotechnologies AG |
| Stadthausbrücke 1-3 | |
| 20355 Hamburg | |
| Germany | |
| Phone: | +41 22 363 66 40 |
| Fax: | +41 22 363 66 41 |
| E-mail: | [email protected] |
| Internet: | www.elanixbiotechnologies.com |
| ISIN: | DE000A0WMJQ4 |
| WKN: | A0WMJQ |
| Listed: | Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf |
| End of Announcement | DGAP News Service |